Inactivated Vaccines Market to Reach US$ 34.26 Billion by 2033 at 4.8% CAGR; Asia Pacific Leads with 41% Share | Key Players Serum Institute of India, GSK, Sanofi

The Inactivated Vaccines Market reached US$ 22.60 billion in 2024 and is expected to reach US$ 34.26 billion by 2033, growing at a CAGR of 4.8% during the forecast period 2024-2032. The market is expanding steadily as inactivated vaccines continue to play a vital role in preventing infectious diseases due to their established safety profile, stability, and widespread use across pediatric and adult immunization programs.

Growth is driven by increasing vaccination coverage, rising prevalence of infectious diseases, and strong support from government and global health organizations for immunization initiatives. Technological advancements in vaccine manufacturing, improved cold-chain infrastructure, and expanding applications in emerging economies are further supporting market expansion. While challenges such as longer production timelines and competition from newer vaccine platforms persist, ongoing public health investments and demand for reliable, proven vaccine technologies continue to sustain market growth.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://www.datamintelligence.com/download-sample/inactivated-vaccines-market?sai-v

Inactivated Vaccines are vaccines made using killed or inactivated pathogens that stimulate an immune response without causing disease, widely used to prevent infectious illnesses.

Key Developments
✅ January 2026: In the United States, vaccine manufacturers expanded production capacity and process optimization for inactivated vaccines to support routine immunization programs and preparedness for emerging infectious diseases.

✅ January 2026: In Japan, pharmaceutical companies advanced inactivated vaccine development and manufacturing technologies, focusing on enhanced safety profiles, scalability, and supply reliability for seasonal and endemic diseases.

✅ January 2026: In Asia-Pacific, governments and healthcare organizations increased procurement and stockpiling of inactivated vaccines to strengthen public health preparedness and immunization coverage.

✅ December 2025: In the United States, regulatory support and funding initiatives encouraged modernization of inactivated vaccine manufacturing facilities, improving quality control and production efficiency.

✅ December 2025: In Japan, vaccine producers collaborated with research institutions to improve adjuvant formulations and antigen stability in inactivated vaccines.

✅ December 2025: In Europe, public health agencies emphasized diversified vaccine platforms, including inactivated vaccines, to ensure resilient supply chains and broad population coverage.

Mergers & Acquisitions
✅ January 2026: In the United States, a biopharmaceutical company acquired a vaccine manufacturing facility specializing in inactivated vaccine production to expand domestic supply capacity.

✅ December 2025: In the United States, a vaccine developer completed the acquisition of a contract manufacturing organization with expertise in inactivated vaccines to enhance vertical integration.

✅ December 2025: In Japan, a pharmaceutical group increased its investment in a vaccine technology company focused on inactivated and traditional vaccine platforms.

✅ August 2025: In Asia-Pacific, a regional vaccine manufacturer acquired a local inactivated vaccine producer to strengthen production capabilities and regional distribution networks.

Key Players
Serum Institute of India Pvt. Ltd. | GSK plc | Sanofi | Biological E Limited | Bharat Biotech | Bio Farma | Merck & Co., Inc. | Valneva SE | Pfizer Inc. | KM Biologics | Others

Key Highlights
Serum Institute of India Pvt. Ltd. holds 24.8% share, driven by its large-scale vaccine manufacturing capacity, cost-efficient production, and strong supply to global immunization programs.

GSK plc holds 16.7% share, supported by its extensive vaccine portfolio, strong R&D capabilities, and long-standing presence in pediatric and adult immunization markets.

Sanofi holds 15.3% share, leveraging its established inactivated vaccine offerings, global distribution network, and strong partnerships with public health organizations.

Merck & Co., Inc. holds 11.9% share, driven by proven vaccine technologies, strong regulatory expertise, and sustained demand for established inactivated vaccines.

Pfizer Inc. holds 9.8% share, supported by global brand strength, advanced manufacturing infrastructure, and integration of vaccines within its broader biopharmaceutical portfolio.

Bharat Biotech holds 7.6% share, driven by strong domestic and international demand, WHO-prequalified vaccines, and innovation in inactivated vaccine development.

Biological E Limited holds 5.4% share, supported by expanding vaccine production capacity and growing participation in global immunization supply chains.

Valneva SE holds 4.1% share, focused on specialized inactivated vaccines and strong presence in travel and emerging infectious disease segments.

Bio Farma holds 2.9% share, leveraging government backing, regional immunization programs, and expanding export activities.

KM Biologics holds 1.5% share, driven by niche inactivated vaccine production and strong presence in the Japanese market.

Buy Now & Unlock 360° Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=inactivated-vaccines-market?sai-v

Market Drivers
- Rising prevalence of infectious diseases and increasing demand for safe and effective vaccination programs worldwide.

- Growing preference for inactivated vaccines due to their established safety profile and suitability for immunocompromised populations.

- Expansion of national immunization programs and government-led public health initiatives.

- Increasing investments in vaccine research, manufacturing capacity, and pandemic preparedness.

- Rising awareness about preventive healthcare and vaccination across developing and developed economies.

Industry Developments
- Expansion of vaccine manufacturing facilities and capacity upgrades to meet global demand.

- Technological advancements in inactivation methods and adjuvant formulations to improve vaccine efficacy.

- Strategic collaborations between pharmaceutical companies, biotech firms, and public health organizations.

- Development of combination and multivalent inactivated vaccines targeting multiple diseases.

- Increased focus on cold chain logistics and distribution infrastructure to support vaccine deployment.

Regional Insights
Asia Pacific - 41% share: "Driven by large population base, strong vaccine manufacturing capabilities, and extensive national immunization programs."

North America - 28% share: "Supported by advanced healthcare infrastructure, strong regulatory frameworks, and high vaccination coverage."

Europe - 24% share: "Driven by well-established public healthcare systems, rising vaccine awareness, and continuous R&D investments."

Latin America - 5% share: "Supported by government immunization initiatives, improving healthcare access, and regional vaccine production."

Middle East & Africa - 2% share: "Driven by expanding vaccination programs, international health funding, and improving healthcare infrastructure."

Speak to Our Analyst and Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/inactivated-vaccines-market?sai-v

Key Segments

By Vaccine Type
Polio vaccines represent a major segment, driven by ongoing global immunization programs and eradication initiatives. DTaP vaccines hold a significant share, supported by routine childhood vaccination schedules and public health mandates. Influenza vaccines account for a substantial segment, driven by seasonal outbreaks and increasing vaccination coverage across age groups. Hepatitis vaccines continue to see strong demand, supported by rising awareness and prevention programs for hepatitis A and B. Japanese encephalitis vaccines represent a notable segment, driven by endemic prevalence in certain regions and government-supported vaccination campaigns. Rabies vaccines are growing steadily, supported by post-exposure prophylaxis needs and zoonotic disease control efforts. Cholera vaccines contribute through outbreak prevention and emergency immunization programs. Other vaccines include those for typhoid, measles, and emerging infectious diseases.

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.